Activation of Polyamine Catabolism in Patients With Acute Pancreatitis
NCT00484042 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2007-06-08
Summary
Background: Polyamines are essential compounds in all mammalian tissues. If tissue spermidine/spermine levels, however, dramatically decrease, the cellular survival is severely endangered. Transgenic animals, where the homeostasis of cellular polyamines can be disturbed and tissue spermidine/spermine levels are decreased, acute pancreatitis evolves, indicating pancreas to be one of the most vulnerable organs for tissue polyamine catabolism. On the other hand, our own data suggests that also in other models of acute experimental pancreatitis pancreatic polyamines are changed depending on the severity of pancreatitis in such a way that the more severe pancreatitis the lower are the pancreatic polyamine levels. Minor changes were observed also in rats undergoing sham operation only. In addition of pancreatic enzymes, inflammatory mediators are also involved in the pathophysiology of the disease. CRP, IL-6, IL-8, IL-10 and Procalcitonin are useful in predicting the severity of the disease, combination of IL-6 and IL-10 at admission can predict organ failure with sensitivity of 95 %, specificity of 88 %.
Hypothesis: Similar to experimental pancreatitis, blood polyamine changes are associated with acute pancreatitis also in the man. These changes are dependent on the severity of pancreatitis, but not on the etiology of pancreatitis. The changes are specific to acute pancreatitis compared with other intra-abdominal emergencies. The changes observed return to baseline during recovery. Furthermore, we assume that blood polyamine negatively correlates with IL-6, IL-8, and procalcitonin, and positively with IL-10.
Conditions
- Pancreatitis
- Polyamines
Sponsors & Collaborators
-
Tampere University
lead OTHER
Principal Investigators
-
Isto H Nordback, M.D. · Tampere University Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-01-31
- Completion
- 2007-06-30
More Related Trials
-
Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease
NCT00808795 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients
NCT00421785 ·Status: UNKNOWN ·Phase: NA
-
Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction
NCT00237614 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy
NCT00492518 ·Status: COMPLETED ·Phase: PHASE4
-
Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
NCT01626911 ·Status: UNKNOWN ·Phase: NA
-
Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein
NCT00463749 ·Status: COMPLETED ·Phase: PHASE3
-
Aminophylline and Contrast Induced Nephropathy in Acute Myocardial Infarction
NCT01594489 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
NCT00247507 ·Status: UNKNOWN ·Phase: PHASE4
-
Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction
NCT01218178 ·Status: COMPLETED
-
Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
NCT00556465 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
N-acetylcysteine in Liver Transplantation
NCT00736541 ·Status: COMPLETED ·Phase: NA
-
Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy
NCT00634491 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels
NCT01075776 ·Status: WITHDRAWN ·Phase: NA
-
N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome
NCT03346681 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Acute Renal Failure Post Liver Transplantation
NCT01907061 ·Status: COMPLETED ·Phase: NA
-
N Acetyl Cysteine for Cystinosis Patients
NCT01614431 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients
NCT00161369 ·Status: COMPLETED
-
Polymorphism of Oxidative Stress Genes in the Pathogenesis and Antioxidant Prevention of Contrast Induced Nephropathy
NCT01142024 ·Status: COMPLETED ·Phase: NA
-
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)
NCT01564303 ·Status: UNKNOWN ·Phase: NA
-
Arginase Inhibition in Ischemia-reperfusion Injury
NCT02009527 ·Status: COMPLETED ·Phase: PHASE1
-
N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Chronic Thromboembolic Pulmonary Hypertension.
NCT04081012 ·Status: UNKNOWN ·Phase: NA
-
Hydration and Contrast-Induced Nephropathy in Primary Angioplasty
NCT00770614 ·Status: COMPLETED ·Phase: PHASE4
-
Hypertrophic Regression With N-Acetylcysteine in HCM
NCT01537926 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of N-Acetylcysteine on Oxidative Stress and Renal Function in Deceased Kidney Transplant Recipients
NCT00851708 ·Status: COMPLETED ·Phase: NA
-
N-Acetyl Cystein and Contrast Nephropathy
NCT01820195 ·Status: UNKNOWN ·Phase: PHASE3